B2B pricing strategy for startups under 20 people for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install B2B pricing strategy has to reflect that reality from day one.

The under-20-person version of B2B pricing strategy is not a diluted enterprise playbook. It is the deliberate choice of unit, level, and packaging that maximises expansion revenue with different constraints: no headcount, no politics, and no time to be wrong for long.

Own it personally as a founder or lean-in operator for the first quarter. Hiring a specialist too early replaces context with process.

Pick one channel, one trigger, one message. Two of anything at this stage is too many and none of them will work.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. B2B pricing strategy is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Instrument net revenue retention in a spreadsheet if you have to. Legibility beats sophistication under 20 people.

The startup-specific trap is matching a competitor instead of pricing to value, usually because a well-meaning advisor points at what worked at their $50m company. Ignore.

Budget rules: whatever you spend on tools, spend the same on the person operating them. Under-tooling is fine; under-humaning is not.

A working B2B pricing strategy function at 15 people is a genuine moat — most competitors of that size do not have one, and the discipline carries forward as the company grows.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing B2B pricing strategy properly rather than half-heartedly across three vendors.